510(k) status inquiries by phone okay for complex resubmissions -- ODE's Alpert.
This article was originally published in The Gray Sheet
Executive Summary510(k) STATUS PHONE INQUIRIES TO ODE are acceptable if a company is following up on the submission of extensive data made in response to an Office of Device Evaluation query, ODE Director Susan Alpert said at a May 6 Regulatory Affairs Professional Society conference in Rockville, Maryland. "If you got a very extensive response" from the agency "or the questions were to every issue in the 510(k), then I suggest you call the branch and find out what your time frame is," Alpert said. However, she added: "I don't encourage you to do it on everything that you submit. In fact, I discourage you from doing that."
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.